Objective: Given that only the free non-protein-bound concentration of an antiepileptic drug (AED) crosses the blood-brain barrier, entering the brain and producing an antiepileptic effect, knowledge and measurement of the free drug fraction is important. Such data are sparse, particularly for newer AEDs, and have arisen from the use of disparate methodologies and settings over the past six decades. We report on the protein binding of 25 AEDs that are available for clinical use, along with two pharmacologically active metabolites (carbamazepine-epoxide and N-desmethyl clobazam), using standardized methodology and under set conditions. Methods: The protein binding of the various AEDs was undertaken in sera of 278 patients with epilepsy. Separation of the free non-protein-bound component was achieved by using ultracentrifugation (Amicon Centrifree Micropartition System) under set conditions: 500 ll serum volume; centrifugation at 1,000 g for 15 min, and at 25°C. Free and total AED concentrations were measured by use of fully validated liquid chromatography/mass spectroscopy (LC/MS) techniques. Results: Gabapentin and pregabalin are non-protein-bound, whereas highly bound AEDs (≥88%) include clobazam, clonazepam, perampanel, retigabine, stiripentol, tiagabine, and valproic acid as well as the N-desmethyl-clobazam (89%) metabolite. The minimally bound drugs (<22%) include ethosuximide (21.8%), lacosamide (14.0%), levetiracetam (3.4%), topiramate, (19.5%) and vigabatrin (17.1%). Ten of the 25 AEDs exhibit moderate protein binding (mean range 27.7-74.8%). Significance: These data provide a comprehensive comparison of serum protein binding of all available AEDs including the metabolites, carbamazepine-epoxide and N-desmethyl-clobazam. Knowledge of the free fraction of these AEDs can be used to optimize epilepsy treatment.
stiripentol, whereas AEDs considered not to be bound include ethosuximide, gabapentin, levetiracetam, pregabalin, and vigabatrin (Tables 1-3 ). The other AEDs are reported to be bound to various degrees between these values.
Routine AED therapeutic drug monitoring (TDM) involves the measurement of serum (or plasma) total concentrations. In most clinical settings, where the relationship between the bound and free unbound components is constant, this approach will suffice. 1 There are, however, clinical settings in which free drug concentrations are significantly higher than expected from total drug concentration measurements; this is particularly the case for those highly bound AEDs. 2 Settings in which this can occur include uremia, hepatic diseases, hypoalbuminemia (e.g., children, the elderly, during pregnancy, postsurgery, burn patients, undernourished, and HIV infection); and suspected plasma protein binding interactions whereby strongly bound drugs compete. [3] [4] [5] [6] Examples of highly protein-bound AEDs that are susceptible to protein-binding impairment are phenytoin and valproic acid. In the case of phenytoin, the free fraction of phenytoin increases, which is followed by increased clearance compensation. The net result is a decreased total concentration level, but normal or higher free levels. Valproic acid shows saturable binding to serum proteins and it may cause binding displacement of other highly protein bound drugs, which does occur when coadministered with phenytoin, and also tiagabine. 5, 6 TDM of total concentration in this setting would be misleading, and only the measurement of free drug serum concentration would relate to the drug's toxicity and efficacy. 5 Measurement of free-drug concentrations can only be undertaken after separation from drug that is protein bound and various methodologies have been described including microdialysis, equilibrium dialysis, ultrafiltration, ultracentrifugation, and gel filtration; each has their advantages and disadvantages. 4 The most frequently used methods are equilibrium dialysis, used in basic/experimental research and considered to be the gold standard method; microdialysis, used for in vivo studies in humans and animals; and ultrafiltration, the method of choice in a clinical laboratory, which provides a routine TDM service because it is convenient to use. 4 Ultrafiltration requires care, as ultrafiltrate volume, temperature and ultrafiltration device, centrifugation time, and membrane used can affect the concentration measurement. 7, 8 Monitoring of free levels is cumbersome and technically challenging because it requires separation of the free fraction, and measurement capabilities may not be sufficiently sensitive to measure the very low concentrations typically encountered. Ultrafiltration is the preferred method to isolate the free drug, as it is relatively simple, adsorption problems have been overcome with technological improvement, 9,10 and precautions can be taken to prevent temperature-dependent effects. 11 Immunoassays and chromatographic methods are used for AED measurements in TDM units. High-performance liquid chromatography (HPLC) and tandem mass spectrometry (MS/MS) coupled together (LC-MS/MS) is the most popular method because it can reliably detect and quantify many different drugs in a single assay. 9, 10 Currently there are at least 25 AEDs licensed for clinical use, and these are categorized into first-generation, secondgeneration, and third-generation AEDs (Tables 1-3) . Overall, there have been numerous reports describing the serum protein binding of the first-generation AEDs, in particular, carbamazepine, phenytoin, and valproic acid. There are sparse data on the binding of the pharmacologically active metabolite of carbamazepine (carbamazepine-epoxide), clobazam, clonazepam, phenobarbital, and primidone (Table 1) . There are no reports of the binding characteristics of the active metabolite of clobazam (N-desmethyl-clobazam); indeed, there is not even a mention of its binding in the clobazam summary of product characteristics (SPCs). Carbamazepine, phenytoin, and valproic acid have more available data, as they were the most substantially proteinbound AEDs and therefore susceptible to protein-binding displacement interactions. Valproic acid also exhibited nonlinear pharmacokinetic characteristics consequent to saturable protein binding, and this phenomenon attracted many investigations. 10, 12 Regarding the second-and third-generation AEDs, there have been few protein-binding studies reported (Tables 2 and 3 ) and, for some (e.g., brivaracetam, felbamate, perampanel, pregabalin, retigabine, rufinamide stiripentol, tiagabine, and vigabatrin), the only data available are those reported in SPCs, which are universally vague and lack details as to methodology or methodology conditions. Perhaps another reason for the lack of binding data for
Key Points
• Epilepsy treatment can be optimized by knowledge of the free fraction of AEDs because only the free nonprotein-bound component enters the brain so as to exert an antiepileptic effect
• Using a standardized methodology, we measured the free fraction of 25 licensed AEDs, including the metabolites, carbamazepine-epoxide and N-desmethyl-clobazam
• The highly bound AEDs (≥88%) include clobazam, clonazepam, perampanel, retigabine, stiripentol, tiagabine, and valproic acid as well as the N-desmethyl-clobazam (89%) metabolite the newer AEDs is that most are considered not to be bound to serum proteins or indeed are minimally bound and therefore not associated with pharmacokinetic variability and consequently lack of clinical significance. Because the available protein binding data have been collected during a 62-year period (1954-2016) using different methodologies and different methodologic conditions, a direct comparison between drugs is not possible. We report on the serum protein binding of 25 AEDs, and including the pharmacologically active metabolites, carbamazepineepoxide and N-desmethyl-clobazam, using a standard methodology (ultracentrifugation; Amicon Centrifree Micropartition System), under set conditions (i.e., 500 ll serum volume; centrifugation at 1,000 g for 15 min, at 25°C). This will allow, for the first time, a comprehensive comparison of AED serum protein binding.
Materials and Methods

Study population
Data were collected retrospectively from adults attending the specialist epilepsy clinics of the National Hospital for Neurology and Neurosurgery (Queen's Square and Chalfont sites), between November 2009 and August 2016, who had serum samples collected for AED concentration determination as part of their routine clinical management. Informed consent was not necessary as this involved data generated as part of routine clinical management.
The samples selected for inclusion were those that had their total AED concentration spanning the quoted reference range for the particular drug. Monotherapy AED samples were preferred, but most samples contained polytherapy AEDs. To avoid potential protein-binding displacement interactions that could have skewed the data, sera containing concomitant known highly protein-bound AEDs (e.g., valproic acid, phenytoin, perampanel, and stiripentol) were excluded when the drug of interest was itself highly protein bound. In total, the protein binding of the various AEDs was undertaken in the sera of 278 subjects.
Sample collection
Blood samples (6 ml) were withdrawn at various times which included predose (i.e., at time zero representing a trough concentration) and up to 5 h post AED ingestion. Sampling occurred during the period 09.00-13.00 h. After clot retraction, blood samples were centrifuged and sera aliquoted into plastic 2 ml microcentrifuge tubes and stored at À80°C until analysis for AED content.
Determination of free concentration Blood samples (6 ml) were withdrawn at various times which included pre-dose (i.e. at time zero representing a trough concentration) and up to 5 h post AED ingestion
We used an Amicon Centrifree Micropartition System (Amicon, Stonehouse, United Kingdom) to separate in serum the non-protein-bound fraction of the various AEDs. Serum (500 ll) was placed on the filter membrane mounted on the sample reservoir and the tube system was centrifuged for 15 min using a Sigma 2K15 centrifuge (1,000 g) with a temperature setting of 25°C. The AED concentrations in whole serum and in the filtrate were determined and the free fraction of the drug was calculated from these values. Free fraction (%) = free concentration/total concentration 9 100. 
Formic acid (analytical grade), and LC/MS grade methanol and acetonitrile were purchased from Sigma-Aldrich (Poole). Ultra-high-quality water was obtained from a Direct-Q system (Millipore, Watford, United Kingdom).
AED analysis
AED free and total concentration analysis was undertaken by LC/MS using fully validated methodologies in routine use within our Therapeutic Drug Monitoring Unit. Validation was based on the most recent versions of the guidelines on bioanalytic method validation of the European Medicines Agency and the U.S. Food and Drug Administration. All AED concentration measurements (free and total) were within the analytic range of the methodologies used. Briefly, an Agilent 1200 series automated LC with an Agilent 6400 series triple quad MS (Agilent Technologies, Stockport, Cheshire, United Kingdom) and a HiQ sil C18 column were used. Sera (24 ll) were extracted with 500 ll acetonitrile and prepared for LC/MS analysis by use of a Gilson Quad-Z215 liquid handler (Gilson Instrumentation Services, Luton, Bedfordshire, United Kingdom). Calibration curve linearity was observed over the concentration ranges typically seen in routine clinical practice and which spanned the quoted reference range for each AED (Table 4) . Table 4 provides a summary of the characteristics of the various AEDs in alphabetical order. In total, the protein binding of the various AEDs was undertaken in the sera of 278 subjects. For each drug, the mean and range of the total and free concentration and the mean percentage free and total concentration values are shown. The laboratory reference range for each drug is also shown; for most AEDs, the serum total concentration measurements were within their depicted laboratory reference ranges. The mean protein binding of N-desmethyl clobazam is 89.2%, almost identical to that of clobazam (90% The protein binding of valproic acid was determined in the serum of 20 subjects treated with sodium valproate in combination with other AEDs. As shown in Figure 1 , the valproic acid free fraction was higher with high serum total concentrations, indicating saturable protein binding of valproic acid. However, interpatient variability in the degree of binding was considerable at any given total concentration value.
Results
Discussion
We present the serum protein binding of 25 AEDs that are licensed for clinical use, along with two pharmacologically active metabolites, using a standard methodology under set conditions. Consequently, these data allow, for the first time, a comprehensive comparison of AED serum protein binding. Our data provide interesting findings on the protein binding of AEDs. With regard to the first-generation AEDs (Table 1) , our data overall concur with previous reports; these include carbamazepine, carbamazepine-epoxide, clobazam, phenobarbital, phenytoin, and valproic acid. The 89% protein binding of the pharmacologically active metabolite of clobazam, N-desmethyl clobazam (Table 4) , is the first report of its binding and is almost identical to that of the 90% binding of the parent drug, clobazam. For clonazepam, its binding is 90% and similar to that of clobazam. These data contrast the 47% binding of clonazepam previously reported 13 using spiked human serum albumin and gel filtration, likely to be due to methodological differences. This may also account for the reported binding of primidone. We found that primidone is 33% protein bound. A previous study using equilibrium dialysis reported a binding of 22%.
14 Another study using ultrafiltration reported that primidone is 13.7% bound. 15 There has been only one previous report of the protein binding of ethosuximide. In a study using a Sephadex column to separate the free from the bound ethosuximide concentration, no significant degree of protein binding was identified, although no actual data were provided. 16 This has led to the belief that ethosuximide binding is negligible. 17 The SPC for ethosuximide states that ethosuximide is "not significantly bound." Using the saliva/serum ratio, an indirect method of determining free serum concentration as it is assumed that serum free levels are in equilibrium with saliva values, ethosuximide binding has been reported to vary from 0% to 5%. 18 The present study reports a mean percentage bound ethosuximide of 21.8 (Table 4) .
We observed that valproic acid binding is saturable within the clinically occurring concentration range so that its pharmacokinetics is nonlinear (Fig. 1) . In addition, considerable interpatient and intrapatient variability in free valproic acid fraction was observed and all these data are in line with those of previous reports. 10, 12 Due to the changing and unpredictable relationship between total and free concentrations, it would be more rational if valproic acid was monitored by measurement of the free drug.
The protein binding of valproic acid appears to be dependent on sample storage and incubation temperature. Free fatty acid concentrations progressively increase with time, and this results in a parallel increase in the valproic acid free fraction. In a study whereby samples were incubated at temperatures varying 4-37°C, at 4°C and room temperature, the increase in free drug fraction was relatively small (18% and 25% at 24 h), whereas at 37°C it was 22%, 34%, and 86% at 4, 8, and 24 h. 19 This time-dependent change in binding capacity may lead to an overestimation of the actual free concentration in vivo. Samples stored at À20°C are stable, with no change in either free fraction or free fatty acid concentrations for up to 6 weeks. 11 These considerations did not pertain to the present study as samples were stored at À70°C and analyzed within 6 weeks of collection. From a practical point of view, if samples are kept refrigerated and the determination of the free fraction is performed within 8 h of blood withdrawal, changes in valproic acid binding capacity are relatively small. Methodology and sample handling appear to be critical in measurement of valproic acid free fraction; it is therefore not surprising that there is wide variability in reported values where disparate methodologies were used (Table 1) .
With regard to the second-generation AEDs (Table 2) , data on the binding of felbamate, gabapentin, pregabalin, tiagabine, and vigabatrin are sparse. The only data available are those reported in SPCs, which lack details as to methodology or methodologic conditions, and their binding is stated to be 22-25%, not bound, not protein bound,~96% and negligible binding, respectively. We found that felbamate is 47.8% bound, tiagabine 97.8%, and vigabatrin 17.1%; pregabalin and gabapentin were not bound. These values are broadly comparable to those quoted in the SPCs.
Previous reports of lamotrigine serum protein binding in vivo, as per saliva/serum distribution ratio, were 46- 56%. 18 We found a mean percentage bound lamotrigine of 65.7 (Table 4) .
A healthy volunteer study of four adults, using ultrafiltration (Amicon Centrifree Micropartition system; temperature not stated), reported that levetiracetam did not bind to serum proteins to any significant extent. It was stated that binding was <1% in all subjects at 1 h after drug ingestion and <1% (subject 1), 3% (subject 4), and 6% (subjects 2 and 3) at 12 h after administration. 20 These data are in line with what we found whereby levetiracetam mean percentage bound concentration was 3.4 (Table 4) .
A study of 17 subjects with epilepsy used three different methods to investigate the protein binding of 10-hydroxycarbazepine (the pharmacologically active metabolite of oxcarbazepine): equilibrium dialysis (37°C), ultrafiltration (enzyme multiplied immunoassay technique [EMIT] free level system-Syva Corporation [SYVA]; ambient temperature), and saliva/serum ratios. 21 Despite the disparate methodologies and conditions, 10-hydroxycarbazepine binding by the three methods was almost identical and was, respectively (mean AE standard deviation [SD]) 40 AE 4%, 45 AE 8%, and 41 AE 12%. Furthermore, these data concurred with that of a study of six people with trigeminal neuralgia whose 10-hydroxycarbazepine binding was 39.0 AE 6.0. 22 The SPC quotes a value of~40%. In a review, 23 it was noted that topiramate was 9-17% protein bound and the SPC states a binding of 13-17%, whereas saliva/serum ratio data report topiramate binding to range 0-37%. 18 Noteworthy is that there is a low capacity binding site for topiramate in/on erythrocytes that is saturable above serum concentrations of 4 mg/L (Topamax -SPC). We report a mean percentage bound topiramate of 19.5 (Table 4) .
Zonisamide protein binding was investigated using ultrafiltration (Amicon Centrifree Micropartition System; temperature not stated) in six healthy volunteers, and a mean AE SD binding of 39.4 AE 1.2 was observed 24 ; this concurred with a value of 40-50% quoted in the SPC. Using the same methodology as in this previous study and at a temperature of 25°C, we found a mean percentage binding of 43.7 (Table 4) .
There is almost no binding data for the third-generation AEDs (Table 3) . Indeed, for brivaracetam (≤20%), retigabine (~80%), and stiripentol (99%), the only data available are those reported in SPCs. We found binding of 35% for brivaracetam, 88% for retigabine, and 96% for stiripentol, and these data are overall comparable with those quoted in the SPCs.
The protein binding of eslicarbazepine is reported in the SPC to be <40%, whereas eslicarbazepine binding is stated in a review to be 30%. 25 Neither publication states the methodology used. We found a mean percentage bound eslicarbazepine of 43.8 ( Table 4) .
The SPC for lacosamide, which does not stipulate methodologic details, reports that lacosamide binding to serum proteins is <15%. In contrast, a study using microfiltration (Amicon Centrifree Micropartition system) with centrifugation at 25°C, observed that protein binding in serum collected from 48 subjects with epilepsy was 91 AE 4%, whereas that calculated from saliva measurement was 87 AE 4%. 26 Using saliva/serum concentration ratio data, a study reported that lacosamide was 2% protein bound after tablet ingestion, whereas binding was 9% after syrup administration; overall, therefore, the value was considered to be <10%. 27 We observed a mean percentage bound lacosamide of 14.0 (Table 4) , which is in accord with that of the SPC and the data from other studies 27, 28 but in contrast to another. 26 The disparate results of this study 26 are perplexing, as the same methodology used in the present study was used.
In a review, 29 it was reported that perampanel in vitro plasma protein binding ranged from 95-96% (data provided by Eisai). These data are in line with that of~95% binding quoted in the SPC. The present study reports a mean percentage bound perampanel of 97.6 (Table 4) .
Finally, in an extensive review, 30 it was reported that rufinamide "in vitro protein binding to albumin ranges from 26.2-34.8%"; these data are referenced as "Eisai data on file" and are in line with that of 34% binding quoted in the SPC. The present study reports a mean percentage bound rufinamide of 27.7 (Table 4) .
The ultrafiltration methodology used to prepare the free fraction of the different AEDs in the present study needs mention. Ultrafiltration is considered to be the method of choice in clinical laboratories that provide a routine TDM service, and this is indeed the practice choice within our TDM Unit; its key feature is convenience of use. 4 Ultrafiltration requires care, as a number of factors can affect the Unbound valproic acid fraction (%) as a function of the total serum concentration in 20 patients with epilepsy receiving multiple antiepileptic drug (AED) therapy with sodium valproate. Those coprescribed highly protein-bound AEDs were excluded from this comparison and thus the potential for protein-binding displacement interactions was not a consideration. Epilepsia ILAE concentration measurement. 7, 8 In an extensive study, the effect of different temperatures on the protein binding of phenytoin (n = 131), carbamazepine (n = 121), and phenobarbital (n = 36) taken as monotherapy was assessed. 8 The Amicon Centrifree Micropartition System was used, and centrifugation was for 20 min at 1,000 g. The free fraction of all three AEDs was observed to be temperature dependent: for phenytoin, the mean value was 0.1 (25°C) and 0.15 (37°C); for carbamazepine, the mean value was 0.26 (25°C) and 0.30 (37°C); and for phenobarbital, the mean value was 0.60 (25°C) and 0.63 (37°C). Of interest, a previous study using the technique of ultrafiltration investigated the effect of temperature (4°C, 26°C, and 40°C) on the protein binding of phenobarbital observed no significant effect and subsequently undertook all further experiments at room temperature and reported that phenobarbital is 40% bound. 31 We report a mean percentage-bound phenobarbital of 47.8, and this is in line with essentially all previous reports (Table 4) . It was reported that the unbound fraction of phenytoin was 0.073 AE 0.007 at 25°C and 0.117 AE 0.008 at 37°C when studied by equilibrium dialysis, and this concurs with subsequent findings. 8 Other variables that can affect free-fraction measurements are that of diurnal rhythms of drug distribution. For example, a study of 12 subjects with epilepsy using ultrafiltration (Millipore Corp, Freehold, NJ, U.S.A.; temperature not stated) in which samples from different times of the day were used, found that valproic acid free drug (%) was 10.6 AE 1.4 in the morning, 12.6 AE 2.2 in the afternoon, and 12.0 AE 2.3 in the evening. Similar diurnal oscillations were observed for phenytoin, primidone, phenobarbital, and carbamazepine. 15 
Conclusion
We report on the serum protein binding of 25 currently available AEDs using a standard methodology under set conditions. The pharmacologically active metabolites, carbamazepine-epoxide and N-desmethyl-clobazam, were also included, and these data allow for the first time a comprehensive comparison of AED protein binding. The AEDs can be divided into those that are highly protein bound (≥88%) and include clobazam, clonazepam, perampanel, retigabine, stiripentol, tiagabine, and valproic acid. Gabapentin and pregabalin are non-protein-bound, whereas the minimally bound AEDs (<22%) include ethosuximide (21.8%), lacosamide (14.0%), levetiracetam (3.4%), topiramate (19.5%), and vigabatrin (17.1%). Ten of the 25 AEDs can be classified as exhibiting moderate protein binding (mean range 27.7-74.8%).
